Related Experiment Video
Updated: May 25, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
P53 and its molecular basis to chemoresistance in breast cancer
Stian Knappskog1, Per Eystein Lønning
1Section of Oncology, Institute of Medicine, University of Bergen, 5020 Bergen, Norway.
Introduction:
TP53 mutations have been associated with resistance to anthracyclines and mitomycin in breast cancer. This review examines the potential roles of different components in the p53 cascade with respect to drug resistance.
Areas Covered:
Literature was searched using the ISI Web and Pubmed. Considering p53 activation in response to genotoxic stress and phosphorylations by ataxia telangiectasia mutated/ataxia telangiectasia and radiation resistance gene 3 related (ATM/ATR). Downstream checkpoint proteins chk1 and chk2 are also considered to be of major importance. Recently, nonsense mutations in CHEK2, encoding the chk2 protein, were found to predict resistance to anthracycline therapy in some tumours harbouring wild-type TP53. While mouse double minute (MDM)2 or MDMX protein overexpression (often due to gene amplifications) may inactivate p53 in different tumour forms, so far, there is no evidence for MDM2 amplifications in breast cancers resistant to anthracyclines. The roles of p53 isoforms and p53-induced transcription of non-coding RNA remain to be defined.
Expert Opinion:
Disturbances affecting the 'p53 pathway(s)' may play a key role in chemoresistance in cancer. Although TP53 is not a clinical marker for drug resistance, like other genes (such as breast cancer associated 1/2 (BRCA1/2)) it may be considered a 'beacon' identifying critical gene cascades.
Insights
TP53 mutations are linked to anthracycline and mitomycin resistance in breast cancer. The p53 pathway
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- TP53 mutations are associated with resistance to anthracyclines and mitomycin in breast cancer.
- This review explores the p53 cascade's role in drug resistance.
Purpose of the Study:
- To examine the role of p53 pathway components in chemoresistance.
- To investigate the impact of TP53 and related genes on breast cancer drug resistance.
Main Methods:
- Literature search of ISI Web and PubMed.
- Analysis of p53 activation, ATM/ATR, chk1/chk2, and MDM2/MDMX roles.
- Review of TP53 isoforms and non-coding RNA in chemoresistance.
Main Results:
- CHEK2 mutations predict anthracycline resistance in wild-type TP53 tumors.
- MDM2/MDMX overexpression can inactivate p53 but lacks evidence in resistant breast cancers.
- The roles of p53 isoforms and non-coding RNA in resistance are not yet defined.
Conclusions:
- Disruptions in the p53 pathway are crucial in cancer chemoresistance.
- TP53, like BRCA1/2, can serve as a 'beacon' for critical gene cascades in drug resistance.
Related Concept Videos
Abnormal Proliferation
Treatment Resistant Cancers
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
